Meet Suzanne Ellis, our new board member

Suzanne Ellis has been appointed to the Board of Directors at Hoptroff, where she will bring her extensive experience in building high-growth profitable businesses and investment management. With her background in managing complex global programmes, launching innovations, and driving continuous improvement in technology and business, Suzanne will help spearhead Hoptroff’s next phase.

Suzanne recently led the demerger of Haleon from GSK, creating a £31.5bn market cap in the FTSE 20. Before leading the demerger, Suzanne led a series of global, complex programmes including GSK-Pfizer Consumer Healthcare integration, GSK-Novartis Consumer Health Integration, GSK Supply Chain transformation, and numerous operating model changes, innovation launches, and tech and business continuous improvement projects. Moreover, Suzanne is a Non-Executive Director at Great Ormond Street Hospital.

David Hulbert, Chairman of Hoptroff, commented: “We are very pleased to have Suzanne join the board. She brings a wealth of experience in both building high-growth profitable businesses and investment management. As Hoptroff continues to grow, I’m sure she will prove to be a valuable member of the Hoptroff family.

Alongside the rest of the board, I welcome the value and the unique perspective she will bring to Hoptroff’s structuring of future deals and investments. Suzanne’s previous experience will help spearhead Hoptroff’s next phase.”

On her appointment, Suzanne says: “I am incredibly excited to be joining Hoptroff Board of Directors. As the digital world increases in speed, precise traceable time will become increasingly important to open many of the opportunities in front of us now and those that lay before us. I passionately believe that Hoptroff is uniquely placed to realise these.

I’m impressed with the trajectory that the company under CEO Tim Richards is heading in, and I’m looking forward to contributing to the growth of the company as we delve deeper into this digital age.”